Sai Life Sciences shares list at 18% premium over IPO price

Sai Life Sciences shares debuted on the exchanges on Wednesday with an 18% premium (Rs 101) at Rs 650 on the NSE. On the BSE, the stock listed with a 16.8% premium (Rs 92.1) at Rs 641.1. Ahead of the listing, the company's shares were trading at a GMP of Rs 72 in the unlisted market."

The IPO received decent demand from all sets of investor’s especially from institutional investors, while retail and NII remained less interested due to expensive valuations along with high portions of OFS in the offer.

"Considering improving market sentiments and all other parameters the company can list with a very decent listing gain around 10% to its issue price," said Prashanth Tapse, Sr VP Research – Research Analyst, Mehta Equities.


Also Read: HUL, don't get Unileverised: The ice cream business melted away, but what’s next?

"Allotted conservative investors can think of booking profits above 15%. While long term investors should consider the company to Hold for Long Term despite knowing short term volatility & risk in the markets. For non-allotted investors, we advise to accumulate if we get dips post listing due to profit booking attempts but for long term only," he said.

The company said that it would use the proceeds from its IPO to repay its debts and for general corporate purposes.

Sai Life Sciences provides end-to-end services across the drug discovery, development, and manufacturing value chain, for small molecule New Chemical Entities (NCE), to global pharmaceutical innovator companies and biotechnology firms.

The global small molecule contract research, development and manufacturing organization industry is forecasted to reach $159 billion by 2028 (comprising approximately 53% of the overall global contract research, development and manufacturing organization industry), driven by increasing pharmaceutical and biotech research & development outsourcing, continued demand for small molecules and growing demand for cost-effective drugs.